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A. SCOPE AND SPECIFIC AIMS
The development of hybridoma technology some thirty years ago rekindled interest in exploiting
the specificity of the antigen-antibody interaction to target radioactivity to tumor for diagnostic and
therapeutic applications.  Despite widespread efforts, radiolabeled monoclonal antibodies (MAbs)
have not had a significant impact on the clinical management of cancer patients.  The marginal
utility of labeled MAbs can be attributed to multiple factors, including those unrelated to antigen
specificity such as Fc receptor binding, vascular clearance and tumor penetration.  Increasing the
utility of labeled MAbs will require optimization of these parameters in concert with improvements
in MAb specificity and radiolabeling.  Our approach will employ DNA recombinant technology to
generate  genetically  engineered MAb-based  constructs  and  evaluate  their  potential  utility  for
oncologic nuclear medicine.  It was the central hypothesis of this proposal that the general
framework of  these  molecules  will  be a  critical  factor  in determining  their  utility  with
radionuclides  and that  the ideal  molecular  form will  also  depend on the  nature of  the
radionuclide, labeling method and route of administration.
Our  work  plan  was  focuseded  on  MAb-based  constructs  reactive  with  tenascin,  a
polymorphic extracellular matrix glycoprotein found in gliomas, neuroblastomas, melanomas, as
well as prostate and breast carcinomas.  Variable regions will be derived from murine 81C6 MAb,
which binds to the alternatively spliced fibronectin type III domain 6 of the tenascin molecule. Our
extensive preclinical and clinical experience using murine 81C6 can serve as a valuable reference
point for the proposed studies.  Moreover, we had obtained promising therapeutic responses with
131I-labeled 81C6 in patients with cystic gliomas, surgically-created glioma resection cavities and
neoplastic meningitis.
This research proposal sought to identify the optimal antibody-based constructs for use with
radionuclides.  Experiments focused on radioiodine nuclides, the -emitter α 211At and the positron
emitter 18F in order to exploit novel radiohalogenation strategies developed in our laboratory.  The
first goal was to select a construct for use with longer half-life nuclides, such as 131I, which can be
best exploited in applications where slow blood clearance and limited tumor penetration are not
major problems.  For this task, chimeric MAbs with constant regions from the four different human
IgG classes  were  constructed,  as  were  molecules  with  domain  deletions  engineered to  alter
pharmacokinetics.   Our preliminary data suggested that use of the IgG2 constant region offers
significant advantages for radionuclide applications.  We also proposed the investigation of sFv
monomers and dimers because their rapid normal tissue clearance and tumor penetration should be
compatible with shorter half-life nuclides such as 18F and 211At.  The specific aims proposed for the
initial grant period in the original application were:
Specific Aim 1a.  To construct and express human/mouse chimeric MAbs for 81C6 with IgG1,
IgG3 and IgG4 constant regions. 
Specific Aim 2a.  To develop human/mouse chimeric 81C6 with domain deletions or alterations in
glycosylation sites.  Engineered immunoglobulins with CH2 domain deletion should offer more
rapid blood clearance similar to that of F(ab')2 but with enhanced stability.
Specific Aim 3a.  To engineer monovalent and divalent sFv recombinant proteins using variable
region cDNA sequences for 81C6.  Heavy- and light-chain cDNA for 81C6 will be cloned via the
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polymerase chain reaction and will be joined via a linker oligonucleotide sequence.  Expression in
Escherichia coli will be optimized with strong promoters. Initially, renaturation and refolding will
be directed towards periplasmic places in E. coli.
Specific Aim 4a.  To label these 81C6 MAb-based constructs with  131I,  211At and  18F using  N-
succinimidyl  [131I]iodo-,  [211At]astato-  and  [18F]fluorobenzoate,  respectively,  with  retention  of
immunoreactivity and affinity.
Specific Aim 5a.  To evaluate the tissue distribution of these labeled molecules in normal mice and
athymic rodents with subcutaneous, intracerebral and neoplastic meningitis xenograft models.
Specific Aim 6a.  To determine the therapeutic efficacy in athymic rodent xenograft models of
promising candidate molecules labeled at equitoxic doses of 131I and 211At.
During the first grant period, our efforts were focused on the evaluation of a chimeric mAb
containing murine 81C6 variable regions and human IgG2 constant regions.  Based on the excellent
tumor targeting and stability of this molecule in animal models, we submitted and obtained an
Investigational New Drug Application to permit its evaluation in patients.  In the second grant
period, we focused on the development and evaluation of anti-tenascin constructs with optimal
properties (mass, valency, domain structure, normal tissue clearance, tumor uptake kinetics and
penetration) for use with short half-life radionuclides. Astatine-211 is a 7.2-hr -particle emitter ofα
considerable  promise  for certain  radioimmunotherapeutic  applications,  13-hr  123I  has  excellent
properties for single photon emission computed tomography, and 1.8-hr 18F is the most frequently
used radionuclide in clinical positron emission tomography.  The specific aims proposed for the
second grant period were:
Specific Aim 1b. To generate higher affinity anti-tenascin constructs via phage display technology.
These studies will utilize a peptide immunogen based on  the amino acid sequence and three-
dimensional conformation of the epitope to which 81C6 binds on domain 12 of the alternatively
spliced fibronectin type III repeat on the tenascin molecule.
Specific  Aim 2b.  To  construct  a  high-affinity,  monovalent,  single-chain  anti-tenascin  mAb
construct with VH and VL domains connected by a peptide linker (scFv), pair of disulfide bonds
(dsFv), or both (scdsFv).
Specific Aim 3b.  To construct a bioengineered, bivalent anti-tenascin mAb construct (either  an
scFv or dsFv dimer, an scFv-CH3 minibody, or CH2 domain deletion construct) with appropriate
properties for radioimmunotargeting. 
Specific Aim 4b.  To determine whether the targeting of these anti-tenascin constructs can be
enhanced  by  minimizing  radiolabel  substitution  on  amino  acid  residues  critical  for  antigen
recognition and tertiary structure. This will be accomplished by either addition of a lysine rich
peptide tail or site-directed mutagenesis of lysine residues in CDR regions.
Specific Aim 5b.  To label the best monovalent and divalent anti-tenascin constructs with 211At, 18F
and radioiodine nuclides, with maximum retention of immunoreactivity, affinity and stability.
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Specific  Aim 6b.  To evaluate  the potential  utility  of  the best  radiohalogenated anti-tenascin
monovalent and divalent constructs for diagnostic and therapeutic applications by determining their
a)  paired-label  tissue  distribution  in  normal  mice  and  athymic rodents  bearing  subcutaneous,
intracerebral and neoplastic meningitis xenografts; b) projected radiation dosimetry from tissue
distribution and quantitative  autoradiography; and c)  therapeutic  potential  in  comparison with
equitoxic doses of  131I- and 211At-labeled anti-tenascin mAbs and fragments.
In the final grant period, we further refined our hypothesis that a multivalent scFv with
high in vivo stability and affinity for tenascin will increase the therapeutic efficacy of 211At due to
its more rapid tumor penetration and clearance from normal tissues.  Our goal was to increase the
clinical potential of radiolabeled anti-tenascin constructs and investigate these hypotheses, and we
proposed the following specific aims:
Specific Aim 1c: To construct a bioengineered, bivalent, anti-tenascin mAb fragment containing
murine 81C6 variable regions and the human IgG2 hinge region.  Our first candidate will be the
CH2 domain deletion construct. 
Specific Aim 2c: To construct a single-chain Fv multimer with adequate stability, affinity and
immunoreactivity for use in tandem with  211At for therapy and 18F for imaging.  Variables to be
investigated include nature of the VL-VH linker,  scFv disulfide stabilization, and link between the
scFv monomeric units.
Specific Aim 3c: To generate higher affinity scFv constructs reactive with the alternatively spliced
fibronectin type III repeats CD of the tenascin molecule via phage display technology and site-
directed mutagenesis. 
Specific Aim 4c: To label promising anti-tenascin constructs with radioiodine, 211At, and 18F and
evaluate  their  potential  as  radiodiagnostic  and radiotherapeutic  agents.   The  proposed studies
include:  characterization of affinity   and immunoreactivity  after  labeling;  evaluation of  tissue
distribution and projected dosimetry in normal  mice,  and athymic  rodents  with  subcutaneous,
intracranial  and neoplastic  meningitis  xenografts;  investigation of  the nature of  low and high
molecular weight labeled catabolites generated in mice; and assessment of cytotoxicity in vitro and
in vivo models of human glioma, and possibly, other tenascin expressing tumors.
Specific Aim 5c: To investigate strategies for labeling scFv monomers and dimers which will
minimize retention of  the  radiohalogen in the  kidneys through the use  of  negatively  charged
templates.
B. RESULTS
1Radioiodinated Chimeric Anti-Tenascin mAb 81C6: Characterization in Comparison with
its Murine Parent
This anti-tenacin chimeric mAb was produced by genomic cloning, and consisted of the
variable region genes of murine 81C6 combined with human IgG2  constant region domains.  The
reactivity  of chimeric 81C6 with recombinant tenascin fragments was identical to that observed for
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murine 81C6; binding was limited to the fragment containing fibronectin III domains 6-12.  In
addition,  the affinity constant for the  binding of  radioiodinated chimeric  and murine 81C6 to
human glioma cells  was  virtually identical.   Nonetheless,  initial  tissue  distribution studies in
athymic mice bearing D-54 MG human glioma xenografts indicated unexpected differences in the
in vivo behavior of the two mAbs: the chimeric molecule (labeled using  Iodogen) exhibited more
than two-fold higher tumor uptake in both subcutaneous and intracranial xenografts and in some
cases, also was retained to a greater degree in normal tissues.
Several experiments were performed in order to explore the nature of the differences in the
in vivo behavior of chimeric and murine 81C6.  The tumor localization of chimeric 81C6 was
compared with that of a nonspecific human IgG2 mAb to determine whether the increased uptake of
chimeric 81C6 in these xenografts was due to specific processes.  Additional investigations were
performed with chimeric and murine 81C6 labeled with  N-succinimidyl  3-[125/131I]iodobenzoate
(SIB) because previous studies demonstrated that murine 81C6 labeled by this method exhibited
superior  tumor  localization  and  inertness  to  deiodination  compared  with  mAb  labeled using
Iodogen.  Our goals were to determine whether higher tumor uptake of chimeric compared with
murine 81C6 also could be achieved using SIB, and whether the tumor delivery advantage of the
chimeric mAb and the SIB labeling method were additive.
In the first tissue distribution experiment, animals received 125I-labeled chimeric 81C6 and
131I-labeled chimeric TPS3.2, a human IgG2 with no known specificity for glioma. The localization
index, defined as the ratio of specific to control mAb in tissue normalized to the ratio of specific to
control mAb measured simultaneously in blood, was calculated to determine the specificity of
chimeric 81C6 tumor accumulation.  Chimeric 81C6 exhibited specific tumor uptake as early as 12
hr after injection with a localization index of 3.3 ± 0.4.  The tumor localization index for chimeric
81C6 continued to rise throughout the course of the experiment, reaching 127 ± 36 on Day 16.
These tumor localization indices were higher than those reported previously for murine 81C6 in
this xenograft model.
In the next experiment, the biodistribution of chimeric and murine 81C6 were compared
after labeling using the SIB reagent.  Blood pool activity of the mAbs was similar at early time
points but by Day 2, there was nearly a twofold difference (chimeric, 14.6 ± 1.8% ID/g; murine 8.0
± 2.0% ID/g; P < 0.05).  By Day 8, blood pool activity of chimeric 81C6 was about 8 times that of
murine 81C6 (chimeric 3.5 ± 1.8% ID/g; murine, 0.45 ± 0.20% ID/g;  P < 0.05).   The tumor
accumulation of both 125I-labeled chimeric 81C6 and 131I-labeled murine 81C6 reached a maximum
on Day 2, with a twofold uptake advantage observed for the chimeric mAb (49.3 ± 16.1% ID/g vs.
29.3 ± 1.3% ID/g).  Chimeric mAb had a fourfold greater tumor retention than murine mAb on
Days 8, 10 and 16. Thyroid accumulation (an in vivo indicator of deiodination) was 0.1% of the
injected dose or less at all time points for both mAbs.  In general, the normal tissue accumulation
of chimeric 81C6 was greater than that of murine 81C6 with the differences increasing with time.  
We next investigated a number of factors which might contribute to the different in vivo
behavior of chimeric and murine 81C6.  First, the sites of labeling on the two mAbs probably are
different since most of the tyrosines and lysines reside in the constant regions. With the Iodogen
method, percent heavy chain labeling observed for chimeric (83%) and murine 81C6 (82%) were
almost identical.  In contrast, when the SIB method was used, 72% of the label was found on the
heavy chain for murine 81C6 compared with 56% for chimeric 81C6.  Because the uptake of
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chimeric 81C6 was greater than its murine parent not only in tumor but also in many normal
tissues, differences in pI between the two IgG could be relevant since the pI of mAbs has been
shown to influence its tissue distribution.   After radioiodination using Iodogen, the isoelectric
point of chimeric 81C6 was 0.5-0.9 pI units higher than that of murine 81C6.  The greater positive
charge of the chimeric mAb is consistent with its higher tissue retention; however, it is not clear
whether the magnitude of the pI difference would be sufficient to account for the observed tissue
uptake patterns.  In addition, the pI of chimeric 81C6 labeled using Iodogen was 7.4-7.6 and the
primary bands with SIB were of similar pI.  Because proteins are least soluble at their pI, it might
be possible that the proximity of the pI of chimeric 81C6 to physiological pH could contribute to
its increased tissue deposition relative to murine 81C6 and nonspecific control mAbs, all of which
have pI dissimilar to pH 7.4. 
The third paired-label study directly compared the tumor and normal tissue retention of
chimeric 81C6 labeled using Iodogen and SIB in order to determine whether the tumor uptake
advantage associated with SIB labeling and use of the chimeric were additive.  Blood clearance of
125I-labeled (Iodogen) and  131I-labeled (SIB) chimeric 81C6 were virtually identical.   Labeling
chimeric 81C6 using SIB reduced thyroid uptake of radioiodine significantly.  The ratio of the %
ID in thyroid for MAb labeled using Iodogen to that for mAb labeled using SIB ranged from 4.6 ±
3.1 at 12 hr to 17.4 ± 6.4 at 4 days.  No other significant differences in normal tissue localization
were observed between the two labeling methods.  Modest improvements in tumor retention were
observed for mAb labeled using SIB on Days 6 (10 ± 6%), 10 (19 ± 6%) and 16 (25 ± 15%), but
differences  were not significant  by  paired  t-test at  other  time points.   With the exception of
stomach,  tumor-to-normal  tissue  ratios  for  mAb labeled using  Iodogen  and SIB were  nearly
identical from 12 hr to 4 days; however, slightly higher ratios were observed at later time points for
chimeric 81C6 labeled using SIB. A more pronounced advantage was seen for SIB in stomach,
reaching a factor of 2 by 6 days after injection.
Because an advantage of SIB is the creation of an iodination site that minimizes recognition
by endogenous deiodinases, the lack of major improvement in tumor uptake of chimeric 81C6
might be related to a low susceptibility of this mAb to deiodination.  This possibility is supported
by the fact that with chimeric 81C6, SIB labeling lowered thyroid by only about 5- to 17-fold
compared with a factor of as much as 108 for murine mAb.  In addition, the thyroid uptake of
chimeric mAb was 2 to 3 times lower than that  of murine mAb in two separate  paired-label
experiments comparing the tissue distribution of chimeric and murine 81C6 labeled using Iodogen.
Taken together,  these  results suggest  that  there are differences  in murine  and chimeric  mAb
catabolism which, depending on the labeling method, may or may not result  in differences in
deiodination.
Catabolism of Radioiodinated Chimeric and Murine 81C6 mAbs
Recently, we have completed an investigation comparing the catabolism of chimeric and
murine 81C6 labeled using Iodogen in athymic mice bearing subcutaneous D-54 MG glioma
xenografts.   Prior to  injection,  both mAbs  were  greater than 99% trichloroacetic  acid  (TCA)
precipitable and moved as a single band on SDS-PAGE with a molecular weight corresponding to
IgG.  Total body retention of 131I(-labeled chimeric mAb) was significantly higher than that of 125I
(-labeled murine mAb) over the first 72 hr and a corresponding increase in the urinary excretion of
TCA-soluble  125I in the urine was seen.  Tumor, liver, spleen and kidney were homogenized to
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examine the nature of the radioactive species in these tissues as well as in the blood.  Tissue
homogenate supernatant were analyzed initially for TCA precipitability to determine the amount of
low molecular weight catabolites.  The percentage TCA-soluble counts was less than 10% for all
tissues at all time points but generally were lower for chimeric 81C6.  For example, the TCA-
soluble percentages for murine mAb in liver, spleen, kidney, blood and tumor were 3.1 ± 0.6, 4.7 ±
0.4, 3.0 ± 0.6, 0.9 ± 0.1 and 9.3 ± 4.6%, respectively, while for chimeric 81C6, these percentages
were significantly lower (P < 0.05): 0.8 ± 0.3, 1.7 ± 0.6, 0.9 ± 0.2, 0.5 ± 0.1, and 1.5 ± 0.5%.
These results suggest that radioiodinated chimeric 81C6 is less susceptible to catabolism than its
murine counterpart.
The  nature of  the  higher  molecular weight  labeled  catabolites  generated  in  vivo was
investigated  using  sodium  dodecyl  sulfate  polyacrylamide  gel  electrophoresis  (SDS-PAGE).
Images of the gels were obtained and the radioactivity in the bands quantified using a phosphor
image analysis system. Dried gels were exposed to a phosphor screen (Kodak) for 48 hr.  The
screen was scanned using a Storm 860 Phosphorimager (Molecular Dynamics) and the resultant
image was analyzed using the ImageQuant analysis program (Molecular Dynamics).  The profiles
of labeled catabolites found in tumor 24 and 144 hr after injection of the labeled mAbs showed that
at 24 hr, approximately 52% of 131I(-labeled chimeric mAb) activity in the tumor homogenate  had
a molecular weight corresponding to intact IgG compared with 38% for 125I(-labeled murine mAb).
Even more striking differences were observed at 144 hr at which time the percentage of tumor
associated radioiodine activity present as intact mAb was more than twice as high for chimeric
compared with murine 81C6.  Similar trends were observed in normal tissues.  The molecular
weight distribution of radioiodine activity at 24 hr for liver, spleen, kidney and blood showed with
the exception of blood, a higher percentage of radioiodine activity was present as intact IgG for the
chimeric  mAb.   A substantial  fraction of radioactivity for murine  but not chimeric  mAb was
present In both tumor and normal organs  as an as yet unidentified 70-90 kD catabolite.  One
possibility is that this molecule was generated by the cleavage of inter-chain disulfide bonds.  In
summary, these results confirm that chimeric 81C6 is more resistant to in vivo catabolism than its
murine counterpart.  It is likely that this difference contributes to the higher tumor and normal
tissue retention of this chimeric mAb.
Enhanced Delivery of Radioiodinated Chimeric 81C6 to Subcutaneous Glioma Xenografts
by Local Hyperthermia
A number of laboratories including our own have demonstrated that local hyperthermia can
improve the tumor accumulation of mAbs and mAb fragments reactive with cell surface antigens.
Because hyperthermia can modulate the expression of cell-surface antigens, typically resulting in
an initial decrease in antigen expression, a mAb directed against a matrix antigen such as tenascin
might be preferable.  The effect of local hyperthermia on the tissue distribution of  125I-labeled
chimeric 81C6 and 131I-labeled chimeric TPS3.2 nonspecific control was investigated.  The D-54
MG subcutaneous glioma xenograft was administered hyperthermia by immersion of the tumor-
bearing leg in a circulating water bath.  Administration of 125I-labeled chimeric 81C6 concomitantly
with a 4 hr, 41.8oC local hyperthermia treatment resulted in a significant (P < 0.005) increase in
mAb  tumor  uptake  immediately  post-heating  from  a  median  of  12.0%  ID/g  of  tumor  in
normothermic mice to 42.0% ID/g in mice receiving local hyperthermia.  The increased level of
tumor uptake persisted in the heated tumors over the first 48 hr after injection, at which time 69.6%
I D/g (vs. 36.6% ID/g for normothermic mice) localized in tumor.  Hyperthermia also increased the
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specificity of tumor localization at 4 hr as reflected by the increase in localization index from 2.21
(normothermic) to 3.35 (heated, P < 0.005).  In addition, heating increased the tumor-to-blood ratio
of chimeric 125I-labeled 81C6 more than 7-fold at 4 hr post-injection.  The rate of tumor uptake also
was dramatically improved, with 60 and 90% of maximum accumulation achieved by 4 and 24 hr,
respectively, in the hyperthermia-treated mice.  In comparison, control mice reached only 31 and
69% of their maximum tumor  uptake  at  those  time points.   In summary,  local  hyperthermia
enhanced both the absolute level and rate of tumor uptake as well as tumor-to-normal tissue ratios
for chimeric  81C6.   This  approach should facilitate  clinical  application of  radionuclides  with
shorter half-lives, such as 211At, for radioimmunotherapy.
Tissue Distribution and Radiation Dosimetry of 211At-Labeled Chimeric 81C6
This study was performed in anticipation of clinical evaluation of  211At-labeled chimeric
81C6 in patients with neoplastic meningitis, cystic glioma, and surgically created glioma resection
cavities.  The  biodistribution  of  211At-labeled  chimeric  81C6  in  mice  bearing  D-54  MG
subcutaneous glioma xenografts was determined and compared to that obtained when labeled with
131I.   These  data  were used  to estimate radiation absorbed doses  in  humans  for  211At-labeled
chimeric 81C6 administered by both the intravenous and intrathecal route.  Mice were injected
intravenously with 211At-labeled chimeric 81C6 (2 Ci, 1 Ci/ g) and μ μ μ 131I-labeled chimeric 81C6
(1.5 Ci, 0.8 Ci/ g) and groups of  5 animals were killed by halothane overdose at 30 min and 2,μ μ μ
4, 8, 16, 24, and 48 hr.
Accumulation of 211At-labeled chimeric 81C6 in tumor increased from 4.5 ± 0.8% ID/g at
30 min to 20.0 ± 3.8% ID/g at 16 hr and remained constant thereafter.  The uptake of 131I-labeled
chimeric 81C6 in D-54 MG xenografts was not significantly different at the 30 min through 8 hr
time points;  however,  131I tumor uptake values were 10-39% higher (P  < 0.05 by paired t-test)
than those for 211At from 16 hr to 48 hr.  Nonetheless, the cumulative activity in tumor per mCi of
211At-labeled chimeric 81C6 was calculated to be 1405 ± 132 Ci-hr/g, a value about 8% lowerμ
than that which would have been predicted using the  131I biodistribution data (1514 ± 106 Ci-μ
hr/g).  These results suggest that serial tumor imaging with a radioiodinated mAb could provide a
reasonable estimate of cumulative activity concentrations that would be obtained when the mAb
was labeled with 211At.
 Activity  concentrations  of  211At-labeled  chimeric  81C6  in  the  athymic  mouse  were
extrapolated to humans using the %-kg/g method. The extrapolated data were fit to one- or two-
compartment  exponential  functions,  and  residence  times  for  source  organs  were obtained  by
integrating the exponential functions to infinite time, including the radioactive decay of 211At, and
assuming  that  the  biological  clearances  observed  continued  beyond the  end of  the  data  sets.
Residence times were entered into a version of the MIRDOSE 3.1 software program modified to
calculate the dose from -emissions.   For all organs, a radiation weighting factor of 5 was appliedα
to the -emissions, and a radiation weighting factor of 1 was applied to all photon and electrons.α
Radiation  dosimetry  calculations  were  performed  for  intravenously  administered  mAb,  mAb
confined to the CSF after intrathecal administration, and for varying degrees of leakage of activity
from the CSF into the vascular compartment.  
Table 2.  Radiation on Dose Estimates for 211At-LabeledChimeric 81C6 Antibody: Effect of
Leakage from Non-Intravenous Injection Site for 5mCi Dose
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______________________________________________________________________________
Radiation Dose (rem)
____________________________________________________
Organ
           1.5%* 5% 10%                    15%
______________________________________________________________________________
Brain 0.14 0.45 0.91 1.36
Small Intestine 0.62 2.07 4.15 6.22
Stomach 0.62 2.07 4.15 6.22
Heart Wall 1.50 5.01 10.02 15.03
Kidneys 1.20 3.99 7.98 11.97
Liver 1.14 3.79 7.57 11.36
Lungs 2.92 9.75 19.49 29.24
Red Marrow 1.54 5.12 10.24 15.36
Spleen 0.95 3.18 6.35 9.53
Thyroid 0.60 2.01 4.02 6.03
Bladder Wall 0.66 2.20 4.39 6.59
______________________________________________________________________________
*Percentage Leakage
 
In patients, the maximum percentage of 131I-labeled murine 81C6 found in the blood pool
during the first 3 days after intrathecal injection has ranged between 3 and 6%.  If one assumes
similar pharmacokinetic behavior in humans for  211At-labeled chimeric 81C6, this leakage level
would correspond to a maximum of  only 1.5% of the administered 211At activity due to the 7.2-hr
half life of this radionuclide. Based on our dosimetry calculations published in [4], and a projected
initial clinical dose of 5 mCi of  211At-labeled chimeric 81C6, we have estimated the dosimetry
which would result if 1.5% to 15% of the 211At activity leaked from a non-intravenous injection site
into the vascular space (Table 2). These calculations indicate that the lungs and red marrow are the
dose-limiting critical organs and that the extent of leakage of 211At into the vascular compartment
will have a major impact on normal organ radiation doses.  Even if the leakage of  211At-labeled
chimeric 81C6 were 10 times higher than  observed in patients with 131I-labeled murine 81C6, the
dose received by red marrow and lungs from 5 mCi of 211At-labeled mAb would be low, about 15
and 29 rem, respectively.  These normal organ doses are lower than those reported for clinical
radioimmunotherapy trials with 131I-labeled mAbs.
Cytotoxicity of 211At-Labeled Chimeric 81C6 for Human Glioma Cells in Microcolonies and
Spheroids
The in vitro cytotoxicity of 211At-labeled chimeric 81C6 was investigated in microcolonies
of the  D-247 MG human glioma and SK-MEL-28 human melanoma cell  lines.   Microcolony
models  were  used  in  an attempt to  simulate  the  tumor  geometry  characteristic  of  neoplastic
meningitis.  D-247 MG microcolonies contained an average of 16 cells at the time of treatment
with an average distance between cells of 22 m.  Cell and nuclear diameters were 18.5 m andμ μ
9.5 m, respectively. SK-MEL-28 cells grew in closely packed colonies consisting of an averageμ
of 25  cells.   The  average  diameter  of  the  cells  and cell  nuclei  was  20.3  m and 10.7  m,μ μ
respectively.   Microcolonies  of  both  cell  lines  were  incubated  for  1  hr  with  varied  activity
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concentrations of  211At-labeled chimeric 81C6, washed to remove unbound activity, and incubated
for an additional 23 hr.  In parallel, the uptake and washout kinetics of labeled mAb in these
microcolonies  was  determined to  provide  cumulative  activity  information  for  microdosimetry
calculations.  These calculations were performed by Gamal Akabani, Ph.D., who joined the faculty
in the Department of Radiology this year.  Monte Carlo transport of -particles was used to assessα
the single-event frequency distribution f1(z) based on the monolayer arrangements described above.
The  activity  concentrations  reducing  cell  survival  to  37% (A37 with  95% confidence
interval) for 211At-labeled chimeric 81C6 were determined by regression analysis to be 56.6(50.0-
64.7) kBq/ml and 61.1(48.2-83.4)  kBq/ml for the D-247 MG and SK-MEL-28 microcolonies,
respectively. Decays were assumed to occur in the cell matrix and the cell nucleus was considered
as the target.  For D-247 MG microcolonies, the calculated average absorbed dose, D37, was 0.27
Gy, the microdosimetric cell sensitivity z0 parameter was 0.10 Gy, and the corresponding number
of hits to the cell nucleus at 37% survival,  〈n〉37, was 1.16.  For SK-MEL-28 microcolonies, D37
was 0.27  Gy,  z0 was  0.14  Gy,  and  〈n〉37 was  1.54.   Differences  in  z0 were large,  reflecting
differences in specific-energy distribution resultant from dissimilar geometrical configurations of
the two microcolony models.  With both cell lines, reduction in survival to 37% required only 1-2
hits to the cell nucleus, confirming the exquisite cytotoxicity of 211At -particles.α
Recently, we have investigated the cytotoxicity of  211At-labeled chimeric 81C6 in the D-
247 MG tumor spheroid model.  Spheroids with a radius of ~100 m, greater than the 55-70 mμ μ
range of 211At -particles, were used.  Hyperthermia at 42α oC for 1 hr was evaluated as a means of
increasing mAb penetration into the spheroid, with the goal of improving the homogeneity of
radiation dose deposition.  This heating protocol was selected because it was not cytotoxic to the
spheroids.   Time to reach 25 times initial volume was used as the endpoint for tumor growth
delay.  This volume was reached in 8.7 days in the groups incubated for 1 hr at both 37oC and 42oC
without mAb.  A significant regrowth delay (median ± 95% confidence interval) was achieved at
activity concentrations as low as 125 kBq/ml {10.9(9.9-12.0) days at 37oC; 10.5(9.6-11.4) days at
42oC}.  At 250 kBq/ml, a 25-fold increase in spheroid volume required 14.8(13.2-16.5) days  at
37oC and 16.0(14.3-17.9) days at 42oC.  No significant increase in cytotoxicity was seen for groups
receiving hyperthermia compared with normothermic controls. Spheroids were incubated with 125I-
labeled  chimeric  81C6,  sectioned  and  autoradiographs  were  obtained  to  determine  whether
hyperthermia increased the penetration of mAb into the spheroids.  Even after 4 hr heating at 42oC,
the radiolabeled mAb was largely confined to the outer layers of the spheroid.  We believe that this
behavior reflects the limited diffusion of intact mAb as a consequence of its large size.   One
approach to minimizing this problem is the use of lower molecular weight constructs such as those
proposed in this grant application.
Radiotoxicity of [211At]astatide and 211At-labeled Chimeric 81C6
One of the impediments to the evaluation of 211At-labeled compounds in patients is the lack
of information concerning the acute, subacute and chronic toxicities of these potential therapeutic
agents. Because deastatination in vivo can occur, gaining an understanding of the toxicity of [211At]
astatide is an important step in the development of 211At-labeled therapeutic agents such as mAbs
and mAb fragments.  With this goal in mind, we have investigated the toxicity and established the
LD10 (dose that killed 10% of exposed animals) of intravenously administered [211At]astatide in two
murine models.  Three dose escalation experiments were performed in groups of 10 B6C3F1 mice
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(the standard strain used by the National Toxicology Program for carcinogenesis testing) and one
dose  escalation  experiment  was  carried  out  in  BALB/c  (nu/nu)  mice  (the  strain  used in  our
laboratory for biodistribution and radiotherapy protocols).  Animal weights were monitored daily
and all autopsies were performed within 12 hr of death.
In B6C3F1 mice, the LD10 (with 95% confidence interval) at 365 days was 15.1 Ci (5.2-μ
19.1 Ci) per animal, equivalent to 0.76 Ci/g (28 kBq/g) body weight.  A 37.8% weight lossμ μ
relative to saline controls (P < 0.001) was observed.  The LD10 in BALB/c (nu/nu) mice was 7.7
Ci (0-14.2 Ci) per animal, equivalent to about 0.35 Ci/g (13 kBq/g).  High [μ μ μ 211At]astatide doses
in B6C3F1 mice were associated with thyroid ablation, severe bone marrow depression, testicular
atrophy, focal alopecia, and nuclear atypia of the epidermoid mucosa of the fore-stomach.  At
activity levels approximating the LD10, mild changes in the heart, liver and stomach were observed
at 360 days; similar effects were seen in the group of BALB/c (nu/nu) mice receiving 10 Ci ofμ
[211At]astatide.
We next initiated an investigation of the toxicity of 211At-labeled chimeric 81C6 in B6C3F1
mice.  Because the pragmatic motivation of these studies was to provide data in support of an
Investigational New Drug application, we sought the advice of the FDA on the design of the
toxicity protocols.  Although the first clinical studies of  211At-labeled chimeric 81C6 will involve
non-intravenous routes (intrathecal,  neoplastic meningitis;  intracystic,  surgically created glioma
resection cavity), it was decided to administer the labeled mAb intravenously to represent the worst
possible case scenario of total leakage of activity from the injection site into the blood pool.  A
dose-finding experiment was performed in which groups of 10 mice received either saline or 14,
29, 63, or 110 kBq/g of 211At-labeled chimeric 81C6.  All of the animals in the high-dose group
died between 5 and 8 days, while no deaths were observed in any other group over the 50-day
observation period, suggesting a maximum tolerated dose of 63-110 kBq/g.
A second toxicity study was carried out at four dose levels in groups of 30 animals per
group, each containing 15 males and 15 females.  Male groups received saline or 15, 16, 51 or 81
kBq/g of 211At-labeled chimeric 81C6; females received saline or 16, 17, 55 or 83 kBq/g of labeled
mAb.  Five mice per sex (total of 10) were terminated at 6 months and examined pathologically,
and the remaining animals were followed for one year after injection.  Survival studies in the 6-
month groups showed no deaths in any of the female groups.  In the males, 1/5 animals receiving
82 kBq/g died on day 9; all other animals remained alive. In female mice followed for 1 year, 5/10
mice died in the 83 kBq/g group (range, 69 to 309 days), 1/10 died at 55 kBq/g on day 330, and
1/10 died when treated with 16.9 kBq/g on day 216.  There were no deaths in mice treated with
15.6 kBq/g or saline.  In the males, 4/9 mice treated with 81 kBq/g died (range, 73 to 164 days),
and 1/10 mice treated with 16.2 kBq/g died on day 296.  There were no deaths in mice treated with
51 kBq/g, 14.9 kBq/g or saline. A preliminary analysis of these data suggest that the LD10 for 211At-
labeled chimeric 81C6 is greater than 50 kBq/g for females and even higher for males.  These
results suggest that the toxicity of the 211At-labeled mAb in this mouse strain is about half that of
free [211At]astatide.  All animals received a complete autopsy within 12 hr of death.  Sections of
tissue from the heart, liver, lungs, kidney, spleen, testes or ovaries, thyroid, stomach, small and
large intestine, and bone marrow were obtained.  Comprehensive histological analysis of the tissue
samples from all 150 animals are currently underway.
Preparation, Purification and Evaluation of scFv 81C6
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We have successfully engineered, expressed and purified a single-chain Fv (scFv) for 81C6
anti-tenascin mAb.  In order to engineer this molecule,  DNA fragments encoding the variable
region cDNA for the heavy- and light-chains were obtained by PCR amplification of oligo-dT
primed poly(A1+) tail of mRNA from the 81C6 hybridoma cell line.  cDNA for the VH and VL
regions of 81C6 were ligated via the linker sequence GGC GGA GGG GGA TCC GGT GGT GGC
GGA TCT GGA GGT GGC GGC AGC which encodes the peptide sequence (Gly4-Ser)3.  The
PCR-primers had additional sequences including those for a linker, a stop codon, and restriction
sites.  Moreover, we constructed primers in such a way that tyrosine, lysine, histidine and cysteine
residues could be added at the tail region.  Tyrosine and lysine residues were included to facilitate
radiohalogenation, cysteine residues to help in producing divalent forms of scFv, and a histidine
tail to aid in further purifying the scFv with (Ni2+) affinity chromatography.  
The 81C6 scFv was expressed and produced in E. coli strain BL21( DE3).  Expression ofλ
recombinant antibody fragments in bacteria is advantageous because with this approach,  large
quantities of cloned gene products can be generated in relatively short time periods, at low cost,
and with homogenous quality.   We employed a secretion strategy for the production of 81C6
because it simplified the purification of the fragment in an active form.  The 81C6 scFv protein
purified by a combination of affinity chromatography and gel-filtration by HPLC, had a molecular
weight of 28 kDa. Its purity was confirmed by gel filtration chromatography using a TSK 2000SW
column and by SDS-PAGE.
Initial  attempts  to  measure  the  binding  affinity  of  81C6  scFv  were  performed  in  an
inhibition assay using D-247 MG cells and chimeric 81C6 as the competitor; unequivocal specific
binding of the scFv could not be demonstrated.  Studies are underway to determine the binding of
81C6 scFv before and after labeling using our newly developed assay (described in Methods
section)  which  utilizes  fibronectin  domains  6-12  of  tenascin  coupled  to  magnetic  beads.   In
addition,  We  are  also  currently  employing  an alternative  approach using  the  in  vitro redox-
shuffling refolding protocol (Buchner et al., 1992) to denature and renature the recombinant scFv
protein.  
Implications of 81C6 scFv Structure for Radiolabeling
Because the major goal of this project involves radiolabeling 81C6 scFv, it is important to
avoid loss of antigen binding capacity due to substitution of the label in the hypervariable regions
(CDRs) of the molecule which are vital for antigen recognition. The vast majority of approaches
for labeling proteins with metal or halogen radionuclides involve substitution on the -amino groupε
of lysine residues,  while direct iodination methods substitute  the iodine  ortho to the hydroxyl
group on tyrosine residues.  With intact mAbs, a knowledge of the position and accessibility of
these amino acids generally is not needed because the large number of constituent lysines and
tyrosines  makes the probability  of  modifying a  critical  residue  relatively  low.   For  example,
chimeric 81C6 IgG has a total of 94 lysines and 58 tyrosines, and there are a sufficient number of
lysines and tyrosines outside the CDRs that it can be labeled using either SIB or Iodogen and
maintain an immunoreactive fraction greater than 80%.   Of the tyrosines in chimeric 81C6, 20%
are in the CDRs and 46% are in the variable regions as a whole; for lysines, these percentages are
lower, 6% and 27%, respectively.  The percentages of tyrosines and lysines observed in the CDRs
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for chimeric  81C6 are similar  to  those  reported  for another  chimeric  mAb,  HuM195  (23.3%
tyrosines, 6.3% lysines). 
  
Compared with intact mAbs, the smaller size of scFv molecules increases the probability
that radiolabeling will occur in the CDR regions because lysines with high reactivity may not be
available in other regions of the molecule.  The number and location of the lysine and tyrosine
residues in 81C6 scFv was determined by examining its amino acid sequence. As summarized in
Table 3, the 81C6 VH chain contains 5 lysines in the framework regions (FR) and 2 in CDR2,
while the VL chain has 3 lysines in the FRs and 1 in CDR1.  If one assumes that all 11 lysines are
equally available for labeling and that substitution in the CDR destroys binding to tenascin, then
the maximum immunoreactivity expected would be 8/11 or about 73%.  Likewise, the 81C6 VH
chain contains 3 tyrosines in the FRs and 4 in CDRs, while the VL chain has 4 tyrosines in the FRs
and 2 in CDR1.  If one assumes that all 13 tyrosines are equally available for labeling and that
substitution  in  the  CDR  destroys  binding  to  tenascin,  then  the  maximum  immunoreactivity
expected for direct iodination would be 7/13 or about 54%.
It is not likely that all tyrosines and lysines have the same reactivity for modification, and
their relative reactivity will be dependent in large part on their accessibility to solvent.  A three-
dimensional model of the 81C6 Fv structure was obtained by comparison with the structure of the
Fv domain of McPC603.  Deletion and mutation of appropriate amino acid residues was performed
using the molecular graphics program GEMM (unpublished, supplied by Dr. B.K. Lee at the NIH)
run on a  Silicon  Graphics  Indigo  workstation.  The  sequence  alignment  scheme used  to  find
corresponding residues was that of Kabat.    As expected for a hydrophilic amino acid, all of the
lysines on 81C6 Fv, including those in the CDRs, appear to be exposed and available for labeling.
The effect of radiolabeling on the immunoreactivity and affinity of 81C6 scFv is not known at this
time.  If major improvements in the binding of lower molecular weight anti-tenascin constructs is
required, two approaches which will be investigated are the addition of a lysine-rich tail and site-
directed mutagenesis.
    Table 3.     The position of lysine and tyrosine residues in 81C6 scFv
                                                                                                                                                   
            Lysine          Lysine         Tyrosine          Tyrosine
                                                                Position       Number              Position           Number   
Heavy chain
CDR1 0 32 1
CDR2 59,65 2 50,60 2
CDR3 0 107 1
FR1 13,19,23 3 27 1
FR2 38 1 0
FR3 66 1 79,93 2
FR4 0 0
Light chain
CDR1 27 1 37,39 2
CDR2 0 0
CDR3 0 0
FR1 0 0
FR2 44 1 41,54 2
FR3 0 86,87 2
FR4 102,1062 0
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  The numbering is according to Kabat et al., (1991) 
Identification of 81C6 Binding Epitope on Tenascin
The long-term objective of this work is to develop mAbs with higher affinity binding to the
same  epitope  on  the  tenascin  molecule  responsible  for  81C6  binding.   Identification  of  the
constituent amino acids of this epitope will allow the synthesis of  peptides which then can be
utilized as immunogens, ultimately leading to the generation of higher affinity, anti-tenascin, scFv
by phage display technology.  Because mAb 81C6 reactivity has been localized to the tenascin
fibronectin  12  domain  (TnFn12),  the  91  amino  acid  sequence  of  TnFn  12  [EAEPEVDNLL
VSDATPDGFR   LSWTADEGVF   DNFVLKIRDT   KKQSEPLEIT   LLAPERTRDL
TGLREATEYE  IELYGISKGR  RSQTVSAIAT T] was synthesized on activated nitrocellulose as
decapeptides, overlapping by eight amino acid residues,  by SPOTS™ technology.  Membranes,
once generated, were probed with murine mAb 81C6, an irrelevant IgG2b murine control mAb, or
buffer alone, followed by horseradish peroxidase-conjugated goat anti-mouse immunoglobulin, and
developed with the ECL enhanced chemiluminescence detection system (Amersham Life Science,
Arlington Heights, IL).  Densitometric analysis of films was performed using the Optimas 6.0
Image  Analysis  system  (Vashaw  Scientific,  Norcross,  GA),  with  inverse  grey  scale  values
corrected for background binding with irrelevant and secondary antibodies.
The results presented below are representative of those obtained in three separate assays.
Analysis of eight amino acid overlapping decapeptides revealed a cluster of positive reactivity for
peptides 9-12, with a single “hot spot” of reactivity for peptide 34.  The peptides so recognized
contain the  common sequence WTADEG,  with  the  greatest binding  occurring  to  peptide  12
[WTADEGVFDN]. Binding to peptide 9 [WTAD] was approximately half that observed to10-12.
This suggested a minimum epitope of WTADEG with optimal binding, possibly including VFDN.
That the latter is not sufficient for binding, and that WT is required for binding, is indicated by the
lack of binding to peptides 13 and 14.  The reactivity detected for spot 34 (TEYEIELYGI) is
apparently unrelated to the reactive cluster at spots 9-12, and is unsupported by any reactivity in
neighboring (33, 35) spots, suggesting an irrelevant (non-variable region binding) attachment by
81C6.  As a result of this analysis, the following peptides were synthesized to determine their
capacity to inhibit the binding of mAb 81C6 to native tenascin:  pep 10 (WTADEG-SGGL-biotin),
minimal epitope; pep 12 (WTADEGVF-SGGL-biotin), pep 14 (RLSWTADEGVFDNF), and pep
14 c (RLSWTADEGVFDNGC).  Pep 10 and 12 contained the presumed inert linker SGGL for
biotin conjugation, and pep 14 c contained a carboxyl-terminal cysteine to allow coupling to KLH
for eventual immunization.   Pep 14 represented the  optimal  binding peptide as determined in
SPOTSscan, extending 3 amino acids towards the amino terminus and one amino acid toward the
carboxyl terminus.  In addition, the irrelevant 14-mer peptide (LEEKKGNYVVTDHC, pep-3) was
investigated.
  
The ability of SPOTSscan-identified peptides to inhibit the binding of 81C6 was assayed.
Relevant peptides were commercially synthesized and conjugated to BSA by coincubation of 0.5
mg peptide with 1.3 mg BSA in 0.01 N Na0H, with the pH adjusted to 7.0 with 0.1 N HCl.
Glutaraldehyde (100 l, 0.25% solution) was added and the reaction allowed to proceed for 2 hr atμ
room temperature.    The  reactivity  of  chimeric  mAb 81C6  for  cell-elaborated  tenascin  was
determined by standard radioimmunoassay (CS-RIA).  The 50% endpoint concentration for H80
14
clone 3-elaborated tenascin was determined to be 0.5 g/ml in this assay.  This concentration ofμ
chimeric 81C6 then was exposed to a series of either free or BSA-bound synthetic peptides in
increasing  molar  amounts  (10,  40,  100,  or  400  M peptide  concentration)  overnight  at  4μ oC.
Absorbed, mock-absorbed (chimeric 81C6 absorbed with identical amounts of carrier BSA) and
unabsorbed control chimeric 81C6 then were assayed for binding to cell-elaborated tenascin by CS-
RIA.   The percent  inhibition of  binding of mock or unabsorbed chimeric 81C6 binding was
calculated.  Two assays  were  performed  with  H80  clone  3  monolayers;  similar  results  were
obtained in two assays with D-247 MG monolayers. 
 Optimal inhibition of chimeric 81C6 binding (56-64%) was obtained with pep 14, either
free or BSA-bound at a concentration of 400 M. Lower levels of inhibition were obtained withμ
100 M pep 14 or pep 14-BSA, and 400 M pep 12-BSA.  Absorption with pep 10-BSA (400μ μ
M) resulted in minimal absorption of activity.  Absorption with carrier BSA, pep 14 containing aμ
carboxyl-terminal cysteine (pep 14C), or irrelevant pep 3 in free or bound form did not inhibit
chimeric 81C6 binding.  This analysis suggests that the linear peptide sequence contained in pep
14
successfully competes for chimeric 81C6 binding to cell-elaborated tenascin; addition of a carboxyl
terminal cysteine destroys the inhibitory activity.  The greater inhibitory capacity of the longer
peptide in both free and bound form, and the partial inhibition obtained with pep 12-BSA, suggests
that  conformational  or  topographical  factors  are  important  for  the  binding  of  mAb  81C6  to
tenascin.
Catabolism of Murine and Chimeric 81C6 mAbs 
15
Liver
150
-1
80
110
-1
30
70
-9
0
40
-5
0
<30
0
20
40
60
80
100
150
-1
80
110
-1
30
70
-9
0
40
-5
0
<30
0
20
40
60
80
Tumor
150
-1
80
110
-1
30
70
-9
0
40
-5
0
<30
0
20
40
60
80
100
Spleen
150
-1
80
110
-1
30
70
-9
0
40
-5
0
<30
0
20
40
60
80
100 Kidney
Molecular Weight ( kDa )
Act
ivi t
y (%
)
Molecular  engineering offers  the  possibility of selecting mAb constant  region domains
which are most appropriate for a particular application.   Most chimeric mAbs that have been
labeled  with  radionuclides  were  originally  developed  for  other  purposes,  primarily  antigen-
dependent cell-mediated and complement-mediated cytotoxicity.  For this reason, these chimeric
mAbs were constructed with IgG1 or IgG3 constant regions because of the need for high Fc-receptor
binding (~1 × 109 M-1).  On the other hand, binding to Fc receptors is not advantageous for labeled
mAbs because it could lead to increased accumulation in normal tissues such as liver and spleen.
Because the affinity of human IgG2 for Fc receptors is negligible, an anti-tenascin chimeric mAb
was produced by combining the variable region genes of murine 81C6 with human IgG2 constant
region domains. The specificity and affinity of this chimeric mAb were identical to those of its
murine parent.
Unlike  IgG1 and  IgG3 chimeric  mAbs,  the  tissue  distribution  of  chimeric  81C6  was
considerably  different  from  that  of  its  murine  counterpart  in  several  unexpected  respects.
Retention of radioiodine activity in subcutaneous and intracranial xenografts  was significantly
higher for the chimeric  mAb when labeling was performed using Iodogen,  with the  chimeric
uptake advantage reaching a factor of two at 48 hr after injection.   Particularly at later time points,
retention of activity in some normal tissues and blood also was higher for the chimeric construct.
To determine whether the enhanced tumor localization of the chimeric construct was related to a
specific process, the tumor localization index (defined as the ratio of specific to control mAb in
tumor normalized to the same ratio in blood) was measured.  The tumor localization index for
radioiodinated chimeric 81C6 increased from 3.3 ± 0.4 at 12 hr to 127 ± 36 on Day 16 for chimeric
81C6, indicating that its tumor uptake was highly specific.  Murine and chimeric 81C6 were then
labeled with N-succinimidyl 3-iodobenzoate (SIB), a reagent previously demonstrated to increase
tumor localization and resistance  to  deiodination compared with mAb labeled  using Iodogen.
Labeling with SIB instead of Iodogen lowered thyroid accumulation of chimeric 81C6 by only
about 5- to 17-fold, compared with a factor of as much as 108 for murine mAb.  Furthermore,
when both mAbs were labeled using SIB, the tumor delivery advantage conferred by the chimeric
construct was not observed.  Taken together, these results suggested that the catabolic processing
of the two mAbs might be different.
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Differences in the catabolism of radioiodinated chimeric and murine 81C6 could account
for the enhanced retention of the chimeric mAb in tumor and some normal tissues.  To investigate
this hypothesis, the catabolism of chimeric and murine 81C6, both labeled using Iodogen, was
compared in athymic mice bearing subcutaneous D-54 MG glioma xenografts.   Animals were
killed  1  to  6  days  after  injection  of  the  mAbs,  and  tumor,  liver,  spleen  and  kidney  were
homogenized.  Homogenate supernatants and blood were analyzed for trichloroacetic acid (TCA)
solubility to measure the levels of low molecular weight catabolites.  The percentage TCA-soluble
radioactivity was <10% for both mAbs in all assays; however, less non-protein associated activity
was found for the chimeric mAb in most samples.  At 24 hr, TCA-soluble percentages in tumor
(1.5 ± 0.5% vs. 9.3 ± 4.6%), liver (0.8 ± 0.3% vs. 3.1 ± 0.6%), spleen (1.7 ± 0.6% vs. 4.7 ± 0.4%) ,
kidney (0.9 ± 0.2% vs. 3.0 ± 0.6%) and blood (0.5 ± 0.1% vs. 0.9 ± 0.1%) were significantly lower
(P < 0.05) for chimeric 81C6, consistent with a lower degree of catabolism of this mAb compared
with murine 81C6.
Figure 1.   Distribution of radioiodinated catabolites in D-54 MG human glioma xenograft, liver,
spleen and kidney 24 hr after intravenous injection of  131I-labeled chimeric (black bars) and  125I-
labeled murine 81C6 anti-tenascin mAbs.
SDS-PAGE  followed  by  quantitative  phosphor  image  analysis  was  performed  to
investigate the nature of the  catabolites generated in vivo.  In tumor, 52% of the chimeric 81C6
counts at 24 hr were present in a band corresponding to intact IgG, compared with 38% for murine
81C6 (Figure 1); by 144 hr, the percentage of radioactivity in tumor found as intact mAb for the
chimeric mAb was more than twice that of murine 81C6.  A higher percentage of radioiodine
activity also was present as intact IgG for the chimeric mAb in liver, spleen and kidneys.  A 70-90
17
kDa catabolite was observed in high abundance for murine mAb but not for chimeric mAb in tumor
and normal tissues. The molecular weight of this species is consistent with the cleavage of inter-
chain disulfide bonds in the murine mAb, yielding an Fab-Fc monomer.  
In order to get a preliminary indication of whether the enhanced stability of the chimeric
81C6 construct would offer a practical benefit in our radioimmunotherapy trials, an in vitro assay
was performed in which radioiodinated  murine and chimeric 81C6 were incubated with tumor cyst
fluid.  Tumor cyst fluid was obtained from the surgically created tumor resection cavities of 7
recurrent glioma patients immediately prior to administration of  131I-labeled 81C6 . The samples
were sterile  filtered,  and stored  at  -170oC until  needed.  After  a  4  hr incubation at  37oC of
radioiodinated  chimeric  and  murine  81C6  with  the  tumor  cyst  fluid,  94.7  ±  5.1%  of  the
radioactivity remained as intact IgG for chimeric 81C6 compared with only 79.2 ± 3.8% for murine
81C6 (Figure 2).  In addition,  levels of the 70-90 kDa catabolite (indicated on gel by arrow) were
considerably higher with murine mAb. These results suggest that the chimeric construct is more
inert to proteolytic degradation than its murine counterpart.  We hypothesize that differences in the
hinge region between the two proteins may be partially responsible for the higher stability of
chimeric 81C6.   This is supported by the lower flexibility of the human IgG2 constant region
compared with that of murine IgG2b, and studies showing that greater hinge region rigidity can
decrease solvent accessibility of regions of the IgG molecule to proteases .
Figure 2.  SDS-PAGE of 125I-labeled murine (left) and chimeric (center) 81C6 after incubation for 4
hr at 37oC with cyst fluid from 7 glioma resection cavity patients; quantitative analysis (right); arrow
indicates 70-90 kDa catabolite.
Radiotoxicity of Intravenously Administered 211At-Labeled Chimeric 81C6 mAb
Only limited information has been available concerning the acute, subacute and chronic
toxicities of  211At-labeled compounds, and this has been one of the major impediments to their
clinical evaluation.   With that goal in mind, we investigated the radiotoxicity of  211At-labeled
chimeric 81C6 in B6C3F1 mice using protocols designed based on advice from the FDA.  This
strain was selected because it is the standard strain used by the National Toxicology Program for
carcinogenesis testing.  Although our intended clinical studies with 211At-labeled mAbs all involve
non-intravenous delivery routes, the labeled mAb was given intravenously to represent the worst
possible case scenario of total leakage of activity from the injection site into the blood pool.
 After an initial dose-finding experiment, a second toxicity study was carried out at four
activity  levels in 30-animal  groups,  each containing 15 males  and 15 females.  Male groups
received saline or 15-81 kBq/g of 211At-labeled chimeric 81C6, and females received saline or 16-
83 kBq/g of labeled mAb.  Five mice of each sex were terminated at 6 months and examined
pathologically,  and the remaining animals were followed for one year.   Animal weights were
monitored  daily,  and  all  autopsies  were  performed  within  12  hr  of  death.  The  LD10 for
intravenously administered 211At-labeled chimeric 81C6 was 46 kBq/g in females and 102 kBq/g in
males.   Toxic  effects,  represented  by  marrow suppression,  splenic  white  pulp  atrophy,  and
spermatic maturational delay, were confined to rare animals receiving the highest activity levels of
211At-labeled chimeric 81C6.  Extrapolation of the LD10 values to the 70-kg standard male and the
58-kg standard female yielded LD10 for intravenously administered 211At-labeled chimeric 81C6 of
192 mCi and 72 mCi, respectively.  The differences in LD10 for the sexes is not known at this time.
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Table 4.  Residence Times for At-211 Labeled Species
Our results indicate that the acute  radiotoxicity of intravenously administered  211At-
labeled  chimeric  81C6  in  the  B6C3F1 mouse  strain  was  about  half  that  of  [211At]astatide
(McLendon et al., 1996).    This observation seems counterintuitive given  the relatively slow
clearance of intact mAbs from most normal tissues following intravenous administration.  Using
previously  published tissue  distribution  data   (Garg  et  al.,  1990; Zalutsky  et  al.,  1997),  the
residence  time  (cumulative  activity  concentration  in  organ  divided  by  the  total  activity
administered)  for  both  211At-labeled  chimeric  81C6  and  [211At]astatide  was  calculated.   As
summarized in Table 4, the residence time for 211At-labeled mAb was greater than [211At]astatide in
liver, lungs, heart, kidneys, and blood, comparable in spleen, and less in both the stomach and
small intestine.
The difference in residence time for the two labeled compounds is consistent with the fact
that gastric changes were not found with labeled mAb but were observed in previous long-term
Tissue
Residence time (hr)
211At-labeled chimeric
81C6
[211At]astatide
Liver 0.49 0.17
Spleen 0.04 0.05
Lungs 0.25 0.12
Heart 0.09 0.02
Kidneys 0.19 0.10
Sm. Intestine 0.25 0.31
Stomach 0.13 0.67
Blood 2.49 0.17
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evaluations of the radiotoxicity of [211At]astatide.  On the other hand, the lower toxicity of  211At
when coupled to mAb would not be predicted based on the longer residence time for labeled mAb
in most normal tissues, particularly blood.  Because of the short range of -particles in tissue, the
homogeneity of radiation dose deposition could be a critical factor.  The diffusion coefficient in
tissue for an intact mAb such as 211At-labeled chimeric 81C6 has been calculated to be 6.3 × 10-9
cm/sec, about 1,000 times higher than that for a small molecule such as [211At]astatide.  Given the
7.2 hr half life of 211At, this slower diffusion would suggest that the toxic effects of 211At-labeled
mAb might be confined to regions within a few m of vascular structures.  Blood pool is generally
considered to be a source organ for the calculation of marrow dosimetry.  Thus, it was surprising
that the threshold for marrow toxicity with 211At-labeled chimeric 81C6 was higher than that seen
previously with [211At]astatide even though the residence time in blood for the labeled mAb was
about 15 times higher.  Because of the short range of -particles in tissue, the distribution of decay
sites on a cellular level becomes important in determining marrow dosimetry.  In order to better
understand the toxic effects of 211At-labeled compounds, we propose to determine their distribution
within  critical  organs  at  the  histologic  or  cellular  level,  and  then  calculate  pertinent
microdosimetric parameters.
Astatine-211-Labeled Chimeric 81C6 Cytotoxicity and Microdosimetry
The geometry in which  -particle cytotoxicity is assessed is a critical parameter due to
their short range in tissue.  Because of our clinical interest in treating neoplastic meningitis, which
presents as a thin layer of cells,  a microcolony model was utilized in an attempt to simulate the
geometry of this disease.  The in vitro cytotoxicity of 211At-labeled chimeric 81C6, reactive with an
extracellular matrix protein, was compared to that of  211At-labeled chimeric Me1-14, reactive with
a cell membrane antigen, as well as to  211At-labeled chimeric TPS3.2, a  nonspecific control mAb.
All 3 chimeric mAbs have human IgG2 constant region domains and they were labeled using N-
succinimidyl 3-[211At]astatobenzoate.  Microcolonies were generated from the D-247 MG human
glioma  and  SK-MEL-28  human  melanoma  cell  lines.   The  geometrical  arrangement  of  the
irradiated  cells  and  the  sites  of  decay  relative  to  the  cell  nucleus  were  determined  so  that
microdosimetry calculations could be performed.  D-247 MG microcolonies contained an average
of 16 cells with an average intercellular distance of 22 m; cell and nuclear diameters were 18.5
and 9.5 m.  SK-MEL-28 cells grew in closely-packed microcolonies containing an average of 25μ
cells, with average cell and nuclear diameters of 20.3 and 10.7 m, respectively.  Microcolonies
were incubated with 211At-labeled mAbs for 1 hr, washed to remove free mAb, and incubated for
an additional 23 hr.   In parallel,  the uptake and washout kinetics of the labeled mAbs in the
microcolonies  was  measured  to  provide  cumulative  activity  concentration  data  for  the
microdosimetry calculations.  Incubations were done at mAb excess to simulate conditions likely to
be encountered in patient treatment protocols.
 
Table 5.  Calculated average absorbed dose to the cell nucleus, D37, cell sensitivity value, z0, average
number of hits, 〈n〉37, and fraction of cells with zero hits P(z = 0), at a survival fraction of 0.37
mAb
D-247 MG cells SK-MEL-28 cells
D37 (Gy) z0 (Gy)  〈n〉37 P(z = 0) D37
(Gy)
z0 (Gy)  〈n〉37 P(z = 0)
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81C6 0.27 0.10 1.16 0.31 0.27 0.14 1.54 0.22
Me1-14 0.24 0.05 1.06 0.35 0.29 0.16 1.62 0.20
TPS3.2 0.28 0.09 1.20 0.30 0.29 0.15 1.55 0.21
Average 0.26 0.08 1.14 0.32 0.28 0.15 1.57 0.21
With all 3 mAbs, there was a linear decrease in survival with increasing media activity
concentration and no evidence for a shoulder at low activity concentrations, consistent with the
high LET of 211At -particles. Using the geometries described above and Monte Carlo transport of
-particles,  the single event frequency distribution fα 1(z) was calculated.  As shown in  Table 5,
differences in z0, the intrinsic radiation sensitivity per traversal, for the two cell lines (D-247-MG,
0.08 ± 0.03 Gy; SK-MEL-28, 0.15 ± 0.01 Gy) were consistent with cell geometry dependent
differences in specific energy distribution.  For  211At-labeled 81C6, reduction in survival to 37%
was achieved with an average of 1.16 and 1.54 hits to the cell nucleus for D-247 MG and SK-
MEL-28 microcolonies, respectively, while for 211At-labeled Me1-14, these values were 1.06 and
1.62, respectively. These results demonstrate the exquisite cytotoxicity of  211At-labeled mAbs in
both microcolony models.
Another set of experiments was done to evaluate the cytotoxicity of 211At-labeled chimeric
81C6 in spheroids formulated from the D-247 MG human glioma cell line.  In order to monitor the
potential effect of mAb diffusion on cytotoxic effectiveness, the radius of the spheroids, 100 m,
was greater than the range of 211At -particles.  Incubations were done at both 37oC and 42oC for 1
hr.   Under this geometry, the lowest activity at which a significant growth delay occurred was 125
kBq/ml, a value more than twice the  D37 measured for this cell line in microcolony geometry.
Autoradiography was done to investigate the rate of penetration of the mAb into the spheroid; as
expected for a molecule of this size, only limited penetration into the spheroid occurred even under
hyperthermic conditions.  This supports the use of lower molecular weight, more rapidly diffusing
molecules such as those proposed in this application, as carriers for use in tandem with 211At.
Production of Astatine-211-Labeled Chimeric 81C6 for Clinical Use
Although a strong rationale has existed for some time for initiating clinical trials with
211At-labeled  compounds,  patient  studies  had  been  impeded  by  the  lack  of  appropriate
methodologies  for  producing  clinically  relevant  levels  of  211At-labeled  radiopharmaceuticals.
There are two aspects to this problem.  First, cyclotron targetry and 211At purification systems are
needed to provide large quantities of 211At (greater than 50 mCi) in appropriate chemical form for
chemical manipulation.  And second, the development of labeling and purification procedures that
are appropriate for high-level syntheses under conditions where radiolytic decomposition may play
a  role  are  required.   We  have  developed  procedures which  have  been  implemented for  the
production of clinical  levels  of  211At-labeled mAbs.   These methodologies  have permitted the
initiation  of  the  first  clinical  trial  of  a  211At-labeled  endoradiotherapeutic  agent,  211At-labeled
human/mouse chimeric anti-tenascin 81C6 mAb.  A total of 16 batches of 211At-labeled chimeric
81C6 have been prepared for clinical use,  12 of which were administered to glioma resection
cavity patients.   Three  additional runs  were  successful;  however,  they  were not  administered
because of clinical  complications.   The  last  run yielded  a preparation with acceptable quality
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control characteristics; however, insufficient 211At-labeled mAb was available for injection because
of the retention of high activity levels in the reaction vessel.
Table 6. Production and distillation of 211At for clinical studies
Run Beam
Current (A)
Irradiation
Time (min)
Target
Activity (mCi)
Distilled
Activity (mCi)
Distillation
Yield (%)
1 52 90 60 36 72
2 52 90 53 34 79
3 51 120 76 41 69
4 55 120 82 49 71
5 55 120 89 39 61
6 53 120 78 40 74
7 52 120 93 39 67
8 57 180 127 75 66
9 53 180 123 74 75
10 50 240 143 98 88
11 60 240 144 74 71
12 50 180 121 58 74
13 55 240 178 91 68
14 55 270 174 101 73
15 55 240 172 83 64
16 55 240 143 61 68
Astatine-211  was  produced  at  the  Duke  University  Medical  Center  cyclotron  by
bombarding natural bismuth metal targets with 28.0-MeV -particles using the  209Bi(, 2n)211At
reaction.  The MIT-1 internal target system specifically designed for the production of 211At was
used.   A detailed  description of  the target  plate  and modified distillation system, as  well  as
associated methods, is presented in the Experimental Design and Methods Section.  These  211At
production runs utilized beam currents of 50-60 A -particles and irradiation times of 1.5 to 4.5
hr (Table 6) with a mean yield of 0.75 ± 0.07 mCi/A-hr.  No significant  differences were
observed in 211Atproduction as a function of beam current or irradiation time. The maximum level
of 211At which was produced was 178 mCi after a 4-hr irradiation at 55 A.  The decay-corrected
distillation yield was 67 ± 16%. 
Synthesis of  N-succimimidyl 3-[211At]astatobenzoate (SAB) was begun between 5 and 40
minutes after the end of the distillation, depending on whether the 211At production was performed
during the day,  or for the longer duration runs, beginning at midnight. SAB was prepared by
reacting in a glass vial the  211At in chloroform,  N-succinimidyl  3-(tri-n-butyl-stannyl)benzoate,
tert-butylhydroperoxide,  and  glacial  acetic  acid.   Instead  of  purifying  SAB  by  HPLC,  a
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modification of our previously described silica gel Sep-Pak™ cartridge method  was used.  The pH
of a 10 mg aliquot of chimeric 81C6 was adjusted to a final pH of 8.8-9.2 by the addition of
saturated borate buffer in a 1:1 volume ratio.  The mAb was transferred to the vial containing SAB
and incubated  at  room
temperature for  15  min.   The
reaction was terminated  by  the
addition  of 0.2  M  glycine  in
borate buffer.   The  211At-
labeled chimeric  81C6  was
purified  by size-exclusion
chromatography  using
a  gas- sterilized, 1.5 × 10 cm
borosilicate glass  chromatography
column loaded with Sephadex
G-25.
Yields  for  the
synthesis  of SAB, which eluted  in
the  30% ethyl acetate in hexane
fractions, averaged  54  ±  10%.
The  mean fraction  of  activity
eluted in the hexane  and  8%  ethyl
acetate  in hexane  fractions,
presumably representing  an  Ato
species  and an  astatinated   -
complex with  the  tin  precursor
aromatic ring, was 7 ± 3% and 27 ± 8%, respectively.  The mean activity retained on the column,
most likely in the form of [211At]astatide, was 12 ± 6%.  The radiation dose deposited in the
chloroform solution prior to initiation of the synthesis ranged from 12,500 to 394,300 cGy, and the
dose delivered during the reaction ranged from 60,350 to 159,600 cGy.  Because of the potential
for  radiolytic  effects  on  the  radioastatodestannylation  reaction,  the  correlation  between these
radiation absorbed doses and SAB yield was investigated.  There was no correlation between SAB
yield and the radiation dose received by the reaction mixture.  No correlations were found between
the radiation dose delivered prior to and during the reaction and the fraction of activity either
retained on the cartridge or eluted in the hexane, 8% ethyl acetate in hexane or 30% ethyl acetate in
hexane fractions.
The radiolabeling yield for the coupling of SAB to chimeric 81C6 was 76 ± 8% after a 20
min reaction at room temperature.  The radiation dose to the reaction medium ranged from  399 to
1196 Gy, and there was no significant correlation between radiation dose and coupling yield.  The
fraction of the 211At activity in the clinical preparations that was protein associated, determined by
methanol precipitation,  was 98.5  ± 1.0%.   The fraction of  211At activity which eluted with a
retention time corresponding to intact IgG on size-exclusion HPLC was 96.0 ± 2.5%, with the
remainder present as either aggregates (3.1 ± 2.5%) or low molecular weight impurities (0.9 ±
1.2%).  All preparations had a pyrogen level <0.125 EU/mL and were determined to be sterile.
After  correcting  for  nonspecific  binding,  the  average  immunoreactive  fraction  for  these  16
preparations was 83.3 ± 5.3%.  When the immunoreactive fraction was plotted as a function of the
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radiation dose received by the mAb during radiolabeling and purification,   regression analysis
indicated that these data were best fit by the following equation:  Immunoreactive fraction = 90.8%
-0.010 × radiation dose (Gy).  However, this slight decrease in immunoreactivity with increasing
radiation dose was not a significant effect (r2 = 0.29).
In summary, methods and procedures have been developed for the production of high levels
of  211At  and for  the  preparation  of  sufficient  211At-labeled  chimeric  81C6 to  permit  clinical
evaluation  of  this  promising  therapeutic  radiopharmaceutical.   We  are  working  on  further
refinements of these methodologies to increase the available activity of 211At-labeled mAb per mCi
211At produced, and reduce total synthesis and purification time.  Nonetheless, using our current
methods, we have demonstrated for the first time that it is feasible to produce sufficient levels of
211At-labeled compounds to perform endoradiotherapeutic investigations in patients.
Astatine-211-Labeled  Chimeric  81C6  Phase  I  Trial  in  Brain  Tumor  Resection  Cavity
Patients
Based in large part on the preclinical studies funded by this grant, we were granted an
Investigational  New  Drug  Permit  in  1998  for  the  first  clinical  evaluation  of  a  211At-labeled
endoradiotherapeutic  agent.  The purpose  of  this  Phase  I  trial  is  to  determine the  MTD and
objective  responses  for  211At-labeled  chimeric  81C6  administered  into  SCRC  of  recurrent
malignant glioma  patients.  At-211 offers several advantages for malignant glioma therapy.  First,
211At -particles have a tissue range of only a few cell diameters and are much more cytotoxic than
131I or 90Y -particles.  And second, patient isolation is minimized due to the short half life and lack
of  energetic gamma emissions  for  211At.   The  211At-labeled chimeric  81C6 preparations  were
synthesized as described above, and immunoreactivity was confirmed prior to injection into the
SCRC.  All patients were given potassium iodide beginning 2 days prior to mAb treatment.
To date,  12 patients (11 GBM, 1 anaplastic oligodendroglioma) have received a single
injection of 10 mg of mAb labeled with escalating doses of 211At.  Four were treated at our staring
dose of 2 mCi, three at 4 mCi, four at 6.7 mCi, and one at 10 mCi.  Serial blood sampling and
gamma camera imaging were done over the next 24 hours to determine  211At pharmacokinetics.
Leakage of  211At activity from the cavity was slow, with a mean biological half time of 763 hr,
resulting in  99.1 ± 0.9% of 211At decays occurring within the SCRC. Blood pool levels were only
0.032 ± 0.025% and 0.258  ± 0.432% of the injected dose at 2 and 24 hours, respectively (Table
7).  Clearance of 211At-labeled chimeric 81C6 from the SCRC was considerably slower and leakage
into the blood pool was significantly lower compared with 131I-labeled murine 81C6.  There have
been no dose-limiting hematologic, neurologic or other toxicities associated with this treatment.
The post-treatment survival range for this Phase I study has been 15 to 117 weeks, with 7 of 12
patients surviving for more than 1 year.  Four patients are still alive and being followed 72, 96,
111, and 117 weeks after their treatment.  Calculated radiation doses to the SCRC interface have
been estimated to be between 12,400 and 78,500 cGy, with less than 5 cGy received by normal
brain,  liver,  spleen and bone marrow.   In  this,  the  first  clinical  evaluation of  a  211At-labeled
therapeutic agent, we have demonstrated that it is feasible to produce clinical levels of 211At, and
administer  211At-labeled chimeric 81C6 mAb with minimal toxicity, very high tumor-to-normal
organ dose ratios, and encouraging survival.  Because of these encouraging results, we decided to
evaluate the pharmacokinetics of 131I-labeled chimeric  81C6 in SCRC patients.  Although this has
delayed further accrual in the 211At-labeled chimeric 81C6 protocol, we felt that it was important to
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determine the pharmacokinetics of  131I-labeled chimeric  81C6 in order to be able to select the
better 81C6 construct for the pivotal Phase III 131I study.
 Table 4.  Astatine-211 blood pool activity in patients following administration of 211At-labeled
chimeric 81C6 into surgically created tumor resection cavity
% Total Blood Pool (Decay Corrected)
Patient* 2 hr 24 hr
1 0.006 0.060
2 0.083 0.066
3 0.033 0.463
6 0.033 0.249
7 0.009 0.052
8 0.008 0.029
9 0.046 1.424
10 0.019 0.038
11 0.060 0.160
12 0.022 0.039
*Blood samples not available from Patient s Number 4 and 5
Evaluation  of  131I-Labeled  Chimeric  81C6  in  Patients  with  Surgically  Created  Glioma
Resection Cavities
The  results  of  the  biodistribution  and  catabolism experiments  described  in  preceding
sections of this proposal demonstrate that the chimeric 81C6 is more stable than murine 81C6 both
in the presence of human tumor cyst fluid and in athymic mice bearing human glioma xenografts.
In order to determine whether this enhanced stability would translate into a practical advantage in
our clinical radioimmunotherapy trials, we are investigating the pharmacokinetics, dosimetry and
toxicity  of  131I-labeled chimeric  81C6  administered into the  tumor  resection cavity  of glioma
patients.   To date,  a  total  of  23  patients  have  been  studied,  starting  at  the131I  activity  levels
determined to be the MTD for murine 81C6 in recurrent (100 mCi) and newly-diagnosed (120
mCi) arms. 
Table 8.  Comparison of 131I-labeled chimeric and murine 81C6 in glioma resection cavity patients
                                        
Chimeric Murine
SCRC half life 213 hr 134 hr
Blood pool half life 378 hr 70 hr
Bone marrow dose 1.19 cGy/mCi 0.41 cGy/mCi
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In Table 8, the phamacokinetics and bone marrow radiation dose for 131I-labeled chimeric
were compared with those measured previously for murine 81C6.  Consistent with its greater in
vitro stability in the presence of tumor resection cavity fluid, the clearance of 131I from the SCRC
for chimeric 81C6 was slower than that measured previously for its murine counterpart.   The
SCRC residence times calculated for chimeric and murine 81C6 were 79 and 101 hr, respectively,
indicating that the dose to the SCRC per mCi administered activity was 28% higher for chimeric
81C6.  Although use of the chimeric mAb reduced the rate of leakage of 131I from the SCRC, the
activity which was released into the blood pool cleared much more slowly.  The biological half
time for chimeric 81C6 was an average of about 16 days, a value similar to that reported for human
IgG2.  As a result of the more prolonged retention of the chimeric mAb in the blood, the radiation
absorbed dose received by the bone marrow increased nearly threefold.  Consistent with these
results was the observation of Grade III or Grade IV hematological toxicities in about two thirds of
these patients, a problem that was rarely encountered in patients receiving 131I-labeled murine mAb.
From a practical perspective, the increased retention of chimeric mAb in the SCRC should
be advantageous because less 131I would be required, reducing cost, and the same tumor dose could
be achieved with less exposure to personnel.  In addition, use of 131I-labeled chimeric 81C6 should
make the treatment more convenient and cost effective by shortening the time that the patient must
be isolated in a lead-lined room.  On the other had, this would only be possible if strategies could
be devised which could exploit the longer SCRC retention time while minimizing bone marrow
toxicity.  This has led us to pursue the development of fragments of chimeric 81C6 which contain
the  IgG2 hinge  region domains  but  lack  CH2 and  possibly  other  domains.   In  this  way,  we
hypothesize that it will be possible to retain the stability imparted by the IgG2 hinge in a molecule
which clears more rapidly from the blood pool.
Identification of 81C6 Binding Epitope
Knowledge concerning the nature of the epitope on the tenascin molecule responsible for
81C6 binding will facilitate the development of higher affinity mAbs and fragments with the same
epitope specificity.  For example, a peptide mapping the  binding epitope could be used as  an
immunogen for generating higher affinity mAbs using phage display technology.   Previous studies
had suggested that the binding epitope  for 81C6  was  exclusively  on Domain D,  one  of  the
alternatively spliced fibronectin Type III repeats; however, when the recombinant tenascin Domain
D fragment (TNfn D) was used as an immunogen, only a modest immune response was obtained in
mice immunized with this protein.  We have now evaluated the epitope reactivity of 81C6 on the
tenascin molecule using the recombinant tenascin fragments TNfn A-D, TNfn A-C, TNfn C-D,
TNfn C, and TNfn D and both ELISA and Western Blotting.
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Figure 3.  Analysis of 81C6 binding to recombinant tenascin fragments by ELISA
ELISA was performed against tenascin or the recombinant tenascin fragments by coating 96
well plates with 50 l of 4 g/ml of each protein in 0.1 M carbonate buffer, pH 9.6.  Plates wereμ μ
incubated overnight at 4oC and rinsed with 115 mM phosphate buffer (pH 7.4), 0.05% BSA and
0.05% Brij 35.  Fifty microliters of murine 81C6 or isotype-control mAb (45.6) dilutions were
added to triplicate wells and incubated for 1 hr at room temperature.  Plates were rinsed with the
above buffer,  50 l  (1 g/ml) of biotinylated rabbit anti-mouse IgG was added per well,  andμ μ
incubated  for  30  minutes  at  room temperature.   After  rinsing,  50  l  of  streptavidin-alkalineμ
phosphatase was added per well and incubated for 30 minutes.  Plates were rinsed and 100 l ofμ
substrate was added per well.  The substrate was 200 mM Tris buffer with 0.005M MgCl2 and 4
mg/ml p-nitrophenyl phosphate.  Color was developed for 10-20 minutes at room temperature and
stopped by the addition of 50 l of 20 mM L-cysteine in deionized water.  Absorbancy was read inμ
a  plate  reader  at  a  wavelength  of  405  nm.   The  results,  summarized  in  Figure  3,  clearly
demonstrate that both the C and D alternatively spliced fibronectin Type III repeats must be present
in order  to form the binding epitope for 81C6.
Western Blotting was performed by adding 1-2 g of tenascin or tenascin fragment to eachμ
lane of a 4-20% polyacrylamide gradient gel.  Proteins were reduced with 25 mM DTT in sample
buffer by boiling for 5 minutes prior to loading on to the gel.  After electrophoresis, protein bands
were transferred to 0.22 m nitrocellulose paper using a Bio-Rad semi dry blotter.  The paper wasμ
blocked overnight by soaking in 5% (w/v) milk in 115 mM phosphate buffer.  After blocking, the
paper was rinsed with 115 mM phosphate buffer with 0.05% BSA and 0.05% Brij 35, and then the
blot was soaked for one hr in 1 g/ml 81C6 or 45.6 (isotype control) diluted in the rinse buffer forμ
1 hr.  After rinsing 4 times, the blot was soaked in 0.25 g/ml of HRP-rabbit anti-mouse IgG for 30μ
minutes,  and then rinsed extensively.   Reactivity was detected  by chemiluminescence using a
SuperSignal West Pico kit  (Pierce) and exposing to Kodak Biomax film for 5  to 60 seconds.
Again, 81C6 reacted with tenascin, TNfnA-D, TNfn C-D but not with TNfn A-C, TNfn D, or TNfn
C, indicating that  81C6 binding requires that fibronectin III domains C and D both be present.  
Radioiodinated 81C6 scFv Fragment
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We have engineered, expressed and purified a recombinant anti-tenascin scFv fragment for
81C6.  In order to engineer this molecule, the variable region cDNA for the heavy and light chains
were obtained by polymerase chain reaction (PCR) amplification of the oligo-dT primed poly(A+)
tail of mRNA from the 81C6 hybridoma cell line.  The 81C6 scFv cDNA (VH-linker-VL) was
constructed using the PCR method by combining the VH region sequence and VL region sequence
via the linker sequence GGC GGA GGG GGA TCC GGT GGT GGC GGA TCT GGA GGT GGC
GGC AGC which encodes the peptide (Gly4-Ser)3.  The PCR primers had additional sequences
including those for a linker, a stop codon, and hexa-histidine tag.  The purpose of the histidine tail
was to aid in purification of  the scFv with (Ni2+) affinity chromatography.  The fragment was
cloned into the pMR1scFv vector and the expression was done under T7 promoter control.  The
complete nucleotide and deduced amino acid sequence  of 81C6 scFv,  including  heavy-chain,
(Gly4-Ser)3 linker, light-chain, and His-tag is shown in Figure 3.  The 81C6 scFv was expressed
and produced in the E.coli strain BL21(DE3).
Our initial attempts to produce and purify 81C6 scFv employed a secretion strategy because
it simplifies the purification of scFv in an active form; however, the 81C6 scFv failed to fold
correctly.  BIAcore analysis was performed and the scFv fragment generated by this approach did
not  exhibit  reasonable  binding affinity  for recombinant  tenascin.   We have  now successfully
produced an scFv fragment with good tenascin binding  using a protocol consisting of metal-
chelating affinity chromatography followed by  in vitro redox-shuffling refolding to renature and
purify the recombinant 81C6 scFv protein to near homogeneity as a 26 kDa monomer (Kuan et al.,
2000a).  The binding kinetics of 81C6 scFv to the recombinant TNfnCD fragment were analyzed
by BIAcore and compared with those  of chimeric  81C6.  The KD for 81C6 scFv was 8.6 × 10-9 M,
within an order of magnitude of the value measured for the bivalent intact mAb (Table 9).  In order
to investigate its thermal stability, the scFv was then incubated at 37oC for 48 hr and its binding
parameters were measured again; more than 80% of its binding affinity was maintained.
The 81C6 scFv fragment has been labeled with 131I and 125I in 60-70% yield and  1.8-2.7 mCi/mg
specific  activity  using  the  Iodogen  method.   The  immunoreactive  fraction,  measured  using
recombinant TNfnCD tenascin fragment coupled to magnetic beads as the antigen-positive target,
was greater than 50%. Several tissue distribution studies have been performed in athymic mice
bearing subcutaneous D-54 MG human glioma xenografts in order to evaluate the in vivo behavior
of radioiodinated 81C6 scFv.  In the first experiment, animals received intravenous injections of
125I-labeled 81C6 scFv and as a control, 131I-labeled MR-1 scFv.  MR-1scFv was selected for this
purpose because its isoelectric point, pI = 6.5, is similar to that of 81C6 scFv.  As shown in the left
panel of  Figure 10, the tumor uptake of 81C6 scFv peaked at 6.8 ± 1.4 % ID/g and declined
gradually thereafter.  The specific-to-control scFv tumor uptake ratio reached 19:1 at 24 hr. A
second experiment  was performed in which  131I-labeled anti-Tac scFv, which has a pI  of 9.5,
served as the control  (Figure 10,  right panel), and even higher specific -to-control scFv tumor
uptake ratios were observed.   In the kidney, 125I activity levels were 1.5 to 3.3 times higher than
those for 131I at 0.5 and 1 hr (81C6 scFv, 22.4 ± 2.6%  ID/g; anti-Tac scFv, 76.7 ± 7.2% ID/g at 0.5
hr), suggesting that the lower isoelectric point might have helped at least transiently reduce binding
to the negatively-charged renal tubule.  The relatively slow clearance of 81C6 scFv from tumor
was somewhat surprising and may reflect multimer formation.  Catabolic studies will be performed
to investigate this in detail.
Table 9.  Binding of 81C6 scFv and intact mAb to TNfnCD tenascin fragment measured by BIAcore
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Protein kassoc (M-1 sec-1) kdissoc (sec-1) KD (M)
chimeric 81C6 IgG 7.6 × 106 9.0 × 10-3 1.3 × 10-9
81C6 scFv 1.4 × 106 1.2 × 10-2 8.6 × 10-9
81C6scFv (37oC/4 hr) 9.1 × 105 1.0 × 10-2 1.1 × 10-8
                                   
                        VH FR1 
     TAACTTTAAGAAGGAGATATACATATGGAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTG  60
                             M  E+1 V  Q  L  Q  Q  S  G  P  E  L
20
   CDR1
     GTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTAGC   120
     V  K  P  G  A  S  V  K  M  S  C22 K  A  S  G  Y  T  F  T  S
40
  FR2      CDR2
     TATGTTGTGCACTGGGTGAAGCAGAACCCTGGGCAGGGCCTTGAGTGGATTGGATATATT   180
     Y  V  V  H  W36 V  K  Q  N  P  G  Q  G  L  E  W  I  G  Y50 I
60
  FR3
     AATCCTTTCAATGATGGTACTAAGTACAATGAGAACTTCAAAGGCAAGGCCACACTGACT   240
     N  P  F  N  D  G  T  K  Y  N  E  N  F  K  G  K66 A  T  L  T
80
 
     TCAGACAGATCCTCCAGCACAGCCTACATGGAGCTCAGCAGCCTGACCTCTGAGGAATCT   300
     S  D  R  S  S  S  T  A  Y  M  E  L  S  S  L  T  S  E  E  S
100
     CDR3  FR4
     GCGGTCTATTTCTGTGCAAGAGACATGGGTCGCGAAGGCTTTGCTTACTGGGGCCAAGGG   360
     A  V  Y  F  C92 A  R  D95 M  G  R  E  G  F  A  Y103W  G  Q  G
120
                          LINKER
     ACTCTGGTCACTGTCTCTGCAGGCGGAGGGGGATCCGGTGGTGGCGGATCTGGAGGTGGC               420
     T  L  V  T  V  S  A114G  G  G  G  S  G  G  G  G  S  G  G  G
140
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           VL FR1
     GGCAGC  GATATTGTGATGACGCAGGCTGCATTCTCCAATCCAGTCACTCTTGGAACATCA     480
     G  S  D+1  I  V  M  T  Q  A  A  F  S  N  P  V  T  L  G  T  S
160
                    CDR1
     GCTTCCATCTCCTGCAGGTCTAGTAAGAGTCTCCTACATAGTAATGGCATCACTTATTTG    540
     A  S  I  S  C23 R24 S  S  K  S  L  L  H  S  N  G  I  T  Y  L
180
        FR2                                           CDR2
     TATTGGTATCTGCAGAAGCCAGGCCAGTCTCCTCAGCTCCTGATTTATCAGATGTCCAAC    600
     Y  W35 Y  L  Q  K  P  G  Q  S  P  Q  L  L  I  Y  Q50 M  S  N
200
              FR3
     CTTGCCTCAGGAGTCCCAGACAGGTTCAGTAGCAGTGGGTCAGGAACTGATTTCACACTG   660
     L  A  S  G57 V  P  D  R  F  S  S  S  G  S  G  T  D  F  T  L     220
                                                  CDR3
     AGAATCAGCAGAGTGGAGGCTGAGGATGTGGGTGTTTATTACTGTGCTCAAAATCTAGAA   720
     R  I  S  R  V  E  A  E  D  V  G  V  Y  Y  C88 A89 Q  N  L  E     240
                 FR4                            HIS-TAG
     CTTCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACATCATCATCATCATCAT   780
     L  P  R  T  F97 G  G  G  T  K  L  E  I  K106H  H  H  H  H  H
260
     CATTGA         
786
     C  Stop           
261
 
Figure 9.  The complete nucleotide and deduced amino acid sequence for 81C6 scFv showing heavy
chain, (Gly4Ser)3 linker, light chain, and hexa-histidine tag.
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Figure 10.  Uptake of scFv fragments in D-54 MG human glioma xenografts following intravenous
injection of radioiodinated scFv fragments.  Left, 125I-labeled 81C6 scFv (black bars) and 131I-labeled
MR-1 scFv (white bars);  right,  125I-labeled 81C6 scFv (black bars) and  131I-labeled anti-Tac scFv
(white bars).
Radiolabeled Anti-Tenascin mAbs and Lymphoma
Although our clinical investigations with radiolabeled anti-tenascin mAbs to date have been
limited to patients  with CNS malignancies,  these radiopharmaceuticals might  be useful  in the
diagnosis and treatment of other tenascin-expressing tumors as well.  We have been working with
Dr. David Rizzieri in the Division of Oncology at Duke to investigate whether anti-tenascin mAbs
might be of value in the treatment of non-Hodgkin’s lymphomas (NHL).  NHL of intermediate
grade generally respond to chemotherapy; however, most relapse, and 5 year survival is only about
40%.  A preliminary study was performed to determine tenascin expression in lymphoid tissue and
relate its expression to microvessel density (Rizzieri et al., 1999).  Tenascin expression increased
concomitantly  with  microvessel  density,  consistent  with  the  possible  role  of  tenascin  in
angiogenesis.
Immunohistochemical  methods  were used  to  determine tenascin expression in  biopsies
obtained from 13 NHL patients.  In most patients, serial biopsies were available.   Our results were
highly encouraging; uninvolved sites including bone marrow did not stain for tenascin, but tumor-
infiltrated lymph nodes, marrow, and other tissues were positive.  Furthermore, the intensity of
tenascin staining increased significantly with transformation of the disease to higher grades and
with progression of the disease.  We have now obtained an IND (BB-IND-9124) and Institutional
Review Board  Approval  for  a  clinical  trial  investigating  the  pharmacokinetics  of  131I-labeled
chimeric 81C6 administered intravenously to NHL patients.  The goal will be to determine the
optimal mAb protein dose for saturating tenascin in normal liver and spleen to maximize tumor
uptake  as is  currently done with anti-CD-20 mAbs to saturate  binding to normal  B-cells.   In
addition to differences in normal tissue binding, tenascin and CD20 differ in one other important
respect.  Unlike CD-20, which is primarily expressed in low-grade NHL, high-level expression of
tenascin occurs in intermediate and high-grade NHL.  Thus, if we are successful in developing
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better anti-tenascin constructs, they might be of value for the radioimmunotherapy of lymphoma,
particularly when used in tandem with the -particle emitting radionuclide 211At.
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